Portfolio

Our socially responsible portfolio

GUIDENT LTD

GUIDENT LTD SEEKS TO IMPROVE THE SAFETY AND EFFICIENCY OF AUTONOMOUS VEHICLES AND LAND-BASED DELIVERY DRONES WITH A SOFTWARE PLATFORM FOR REMOTE MONTIORING AND CONTROL.
INVESTMENT RATIONALE

Vehicles of all types are rapidly becoming electric and autonomous. While AV’s are projected to be significantly safer than traditional vehicles, there will still be mishaps and in many instances there will be no vehicle operator present to help resolve these problems. Guident’s remote monitoring and control centre will monitor vehicles and if necessary provide additional support such as call a first responder, take over control of the vehicle to move it out of harm’s way and provide real-time communication with passengers or pedestrians.

With a portfolio of seven patents and its world-class team, Guident delivers competitive advantages for AV fleet operators by providing real-time, passenger & delivery vehicle monitoring and control, for public and private mobility markets.

Guidents initial goal is to build and operate the first Remote Monitoring and Control Center for ground-based delivery drones and AVs in the State of Florida. Recent state law requires back-up, human remote monitoring for AVs when a safety driver is not present in the vehicle. This is a critical path to enable the commercial introduction of AVs in Florida and is likely to be required in other jurisdictions.

Guident also offers an additional patented technology enabling OEM’s to cost-effectively increase the range of their electric vehicles with electromagnetic regenerative shock absorbers. This technology received the R&D 100 Award by R&D Magazine, for one of the 100 most significant technology innovations of the year from around the world.

Founded 2018

Percentage owned: 100%
Sectors: Autonomous Vehicles
CEO: Harald BrauN
Percentage owned: 100%
Sectors: Autonomous Vehicles
CEO: Harald BrauN

SALARIUS LTD

MANUFACTURES MICROSALT®, A NEW, PATENTED, LOW-SODIUM SALT THAT TASTES GREAT AND DELIVERS HALF THE SODIUM OF REGUALR TABLE SALT.
INVESTMENT RATIONALE

The snack food industry is focused on developing and providing better for you products that taste good but provide reduced sodium consumption. The reason for this is that excess sodium consumption contributes to cardiovascular disease, a leading cause of premature death globally. To address this problem, Salarius has developed a patented process for producing micron sized salt crystals that provide all of the flavor of salt with roughly half of the sodium for topical food applications.

Salarius has developed the world’s smallest salt crystals with its patented MicroSalt®. With MicroSalt®, companies can make full flavor snacks with the same saltiness as traditional snacks yet with half of the sodium.

MicroSalt® uses nano-sized sodium chloride crystals that dissolve faster, is all natural, non-GMO, Kosher and doesn’t contain any of the additives found in other sodium reduction products.

The global Sodium Reduction Ingredients Market is expected to reach USD 1.62 billion by 2024 with a CAGR of 7.3% from 2019 to 2024. Salty snack market was worth $26b in 2019 alone. Recently, Microsalt has secured two food brokers and the leading U.S. natural food distributor for its product in the United States and Mexico.

Cardiovascular disease is the world’s leading health problem causing 17.6 million deaths annually and is related to high sodium consumption, especially in snack foods. According to the FDA, reducing daily sodium intake from 3,400 mg to 2,300 mg / day will reduce approximately 28,000 – 50,000 premature deaths per year in the U.S.

Founded 2018

Percentage owned: 97%
Sectors: Food Tech
CEO: Victor Manzanilla
Percentage owned: 97%
Sectors: Food Tech
CEO: Victor Manzanilla

LUCYD LTD

LUCYD IS SEEKING TO UPGRADE YOUR EYEWEAR® BY PRODUCING DESIGNER EYEWEAR WITH SMART FEATURES AT AFFORDABLE PRICES. LUCYD WAS THE FIRST COMPANY TO DELIVER PRESCRIPTION GLASSES WITH BLUETOOTH® TECHNOLOGY IN 2018. THEIR FRAMES HELP YOU STAY CONNECTED SAFELY AND CONVENIENTLY.
INVESTMENT RATIONALE

Pedestrial fatalities have increased by 60% from 2009 to 2018. This is due primarily because drivers and pedestrians alike are distracted with their smartphones. Approximately 2/3 of the population wear corrective lenses. Bluetooth technology has evolved, enabling it to be incorporated into traditionally sized designer eyewear. This enables eyeglass wearer to remain connected to their digital lives such as when taking calls and listening to music while maintaining situational awareness. Individuals can keep their phones in their pocket and no ear buds are required, as the eyeglass frames contain miniature speakers and microphones.

With Lucyd frames, you can stay focused on the world while making calls, listening to music and using voice assistants.

Sitting at the intersection of Hearables, Digital Assistances and Online Eyewear markets, Lucyd is positioned to become a major player in eyewear by offering the only low-profile smart frame, with Rx lenses, at an unbeatable price.

To provide a unique, new wearable experience, Lucyd is also developing a voice-based social media app called Vyrb™. Vyrb will enhance Lucyd frames with social features, such as verbal posting and hashtagging. Lucyd has a pending patent on several features of Vyrb, two utility patents regarding wearable tech, one of which has received a notice of allowance and 28 design patents.

Founded 2017

Percentage owned: 100%
Sectors: Tech Eyewear
CEO: Harrison Gross
Percentage owned: 100%
Sectors: Tech Eyewear
CEO: Harrison Gross

BELLUSCURA PLC

RESPRATORY MEDICAL DEVICE COMPANY THAT HAS DEVELOPED AN IMPROVED PORTABLE OXYGEN CONCENTRATOR (POC) TO PROVIDE ON-THE-GO SUPPLEMENTAL O2 . THE COMPANY BELIEVES ITS PRODUCT WILL BE THE LIGHTEST, AND FIRST MODULAR OXYGEN CONCENTRATOR. BELLUSCURA AIMS TO MAKE POC’s MORE AFFORDABLE TO THOSE THAT NEED THEM.
INVESTMENT RATIONALE

Approximately 250m individuals suffer from COPD. Many of these patients require supplemental oxygen. As there is no cure for COPD  over time patients require greater amounts of oxygen, and if they use a portable oxygen concentrator, this means they must replace their devices with devices with greater capacity as their disease progresses.  With Belluscura’s new patented device, users will be able to  swap out the filter cartridges to enable higher capacity oxygen flow without having to change the device they are using. Like upgrading memory on a laptop. The result is the potential for significantly more affordable oxygen therapy for the life of the patient.

Capable & highly experienced management: Bob Rauker, CEO (previously Boston Scientific) & Dr Raymond Bray, VP (previously St. Jude Medical).

Belluscura plc announced the receipt of 510(k) Clearance from the US Food and Drug Administration (the “FDA”) for its X-PLO2R™ on 8 March 2021

According to Grandview Research, the global medical O2 concentrator market was $1.75bn in 2018 (7.4% CAGR).¹

This innovative device will be especially  helpful when dealing with COVID related respiratory problems. filed a Recently, Belluscura filed a patent application covering devices and systems for treating people suffering from acute respiratory distress caused by the Coronavirus. Belluscura working with its R&D partner Separation Design are designing and developing next generation, cost-effective, portable ECMO technology to treat ARDS patients. 

In May 2021, Belluscura plc commenced trading on the AIM market of the London Stock Exchange.

Founded 2016

Percentage owned: 15%
Sectors: Medical Devices
CEO: Bob Rauker
Percentage owned: 15%
Sectors: Medical Devices
CEO: Bob Rauker